This refresh
Data-driven refresh July 21, 2026. The Top Picks are the Bull Rankings quality-growth screen — strong, growing businesses with durable returns at a fair price (PEG / EV-EBIT vs sector, ROIC, free cash flow). Scanned every US-listed common stock on NYSE, NASDAQ, NYSE American, and NYSE Arca (5,229 tickers); 1,785 scored on the quality-growth model (financials route to a separate card). Fundamentals from Yahoo Finance quoteSummary reconciled with as-reported SEC EDGAR filings; narrative authored by Groq (with Gemini and data-driven fallbacks).
Top Picks — quality compounders at a fair price
1. DOCS — Doximity, Inc. · score 90.6
Health Information Services · price $21.11 · 1Y $24.56 · 5Y $35.95 · 10Y $53.33
FCF $326m C · Rev +13.1% B+ · D/E 0.01 A · P/E 21.5x B+ · PEG 0.59 A-
Why now. DOCS’s moat lies in its AI‑powered clinical workflow tool, Ask, which embeds evidence‑based content directly into physicians’ daily routines, driving sticky engagement and premium ad pricing. The platform’s 13.1% YoY revenue growth, 30.4% profit margin and 20.6% ROE prove that this stickiness translates into high‑margin cash generation, and our Bull Rankings model awards a 90.6/100 quality‑growth score with Growth as the strongest pillar. The thesis hinges on the continued compounding of physician‑level usage and ad spend, which should keep the growth engine humming.
Moat. Ask, Doximity’s HIPAA‑compliant AI assistant, locks clinicians into a single digital hub for news, peer updates, and evidence‑based guidance, creating a network effect that rivals can’t replicate without rebuilding a massive user base. The 20.6% ROE reflects pricing power from being the de‑facto professional platform for U.S. physicians, allowing the company to command premium sponsorship rates while maintaining a lean cost structure.
Risk. The market is pricing DOCS for near‑term optimism: a forward P/E of 21.5 and a reverse‑DCF implied free‑cash‑flow growth of only ~2% per year clash with the actual 13.1% revenue expansion, meaning any slowdown in ad spend or a shift to competing platforms could crush margins. A beta of 1.29 amplifies downside in a volatile market, and a breach of the 52‑week low ($17.15) would signal that the growth premium is evaporating. The bear case materializes if quarterly FCF growth stalls below 2% and the platform’s user engagement plateaus.
Horizon. 1-3 yr $24.56 (analyst consensus (n=18)) — fundamentals + valuation re-rating. 5 yr $35.95 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $53.33 if current growth sustains into durable earnings power.
2. ADBE — Adobe Inc. · score 89.4
Software - Application · price $227.16 · 1Y $273.28 · 5Y $400.12 · 10Y $593.55
FCF $10.3b A- · Rev +11.5% B · D/E 0.61 C+ · P/E 13.0x A- · PEG 0.65 A-
Why now. Adobe’s Digital Media suite continues to dominate the creator economy, and its subscription‑based model fuels recurring revenue that still grew 11.5% YoY. Coupled with an industry‑leading ROE of 62.8% and a massive $10.3B of free cash flow, the business compounds earnings at a rate that outpaces peers, making the next 12‑months a clear upside play.
Moat. The Creative Cloud platform locks in photographers, video editors, and designers through multi‑year licenses and deep integration with Adobe’s Experience Cloud, creating a high switching cost that sustains pricing power and drives the extraordinary 62.8% ROE. This ecosystem lock‑in also fuels cross‑sell opportunities that competitors cannot replicate quickly.
Risk. Adobe’s valuation already assumes a negative free‑cash‑flow growth of about –3% annually, far below its actual 11.5% revenue growth, and a high beta of 1.43 signals heightened sensitivity to market swings; a slowdown in subscription renewals or a successful push from rival SaaS providers could force the stock back toward its 52‑week low of $190.12, confirming the bear case.
Horizon. 1-3 yr $273.28 (analyst consensus (n=34)) — fundamentals + valuation re-rating. 5 yr $400.12 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $593.55 if current growth sustains into durable earnings power.
3. DLO — DLocal Limited · score 88.8
Software - Infrastructure · price $14.77 · 1Y $17.85 · 5Y $26.13 · 10Y $38.77
FCF $413m C · Rev +46.6% A · D/E 0.20 B+ · P/E 23.1x B+ · PEG 0.50 A
Why now. The Bull Rankings model gives DLocal an 88.8/100 quality‑growth score, with Growth as its strongest pillar, because its cross‑border pay‑in platform is fueling a 46.6% YoY revenue surge, a 34.6% ROE and a $413 m free‑cash‑flow runway — a rare high‑quality compounder in payments. The thesis rests on the continued expansion of e‑commerce, streaming and ride‑hailing merchants that need DLocal’s one‑stop global payment stack, which should keep the growth engine humming for years to come.
Moat. DLocal’s moat is its integrated pay‑in and pay‑out suite that locks merchants into a single gateway for hundreds of alternative payment methods, creating high switching costs and network effects. This breadth lets the company command pricing power, evident in a 34.6% ROE, and the platform‑as‑a‑service model (dLocal for Platforms) deepens relationships with large SaaS and marketplace customers that are hard for rivals to replicate quickly.
Risk. The bear case centers on the model’s dilution signal and the reverse‑DCF implied free‑cash‑flow growth of –6%/yr, which is far below the 46.6% revenue growth and suggests the market may be over‑pricing future cash generation; a slowdown in merchant adoption or a pricing squeeze would push the PE 23.1 to unsustainable levels. Confirmation of the risk would be a widening of the P/E or a missed earnings beat that forces the price below the 52‑week low of $9.81.
Horizon. 1-3 yr $17.85 (analyst consensus (n=10)) — fundamentals + valuation re-rating. 5 yr $26.13 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $38.77 if current growth sustains into durable earnings power.
4. INTU — Intuit Inc. · score 88.7
Software - Application · price $289.92 · 1Y $473.68 · 5Y $693.52 · 10Y $1,029
FCF $7.8b B+ · Rev +15.1% B+ · D/E 0.33 B · P/E 17.7x A- · PEG 0.76 A-
Why now. Intuit’s QuickBooks Online platform is the engine, delivering 15.1% FY revenue growth, $7.8B free cash flow and a 21.9% profit margin, all while the market still values the business at a modest PE of 17.7x. The Bull Rankings model awards a Growth pillar of 95, confirming that the SaaS‑driven subscription base will keep compounding, and the 1‑yr analyst consensus of $473.68 signals near‑term upside. The thesis hinges on QuickBooks’ sticky SMB subscription base continuing to expand at double‑digit rates.
Moat. QuickBooks embeds itself in the daily accounting workflow of millions of small‑ and mid‑market businesses, creating high switching costs and a data moat that fuels cross‑sell of payroll, payments and financing. This lock‑in drives the 22.2% ROE, as Intuit can price premium services on a captive user base that rivals can’t replicate quickly.
Risk. The biggest headwind is the premium valuation: a PE of 17.7x is high for a mature software name and the reverse‑DCF shows the market is pricing ~‑6% annual FCF growth for the next decade, far below the 15% revenue growth reality. A slowdown in SMB spending or a pricing squeeze would force the multiple down, confirming the bear case. A sustained dip in the PE or a missed earnings beat would trigger a sell‑off.
Horizon. 1-3 yr $473.68 (analyst consensus (n=33)) — fundamentals + valuation re-rating. 5 yr $693.52 at ~19% CAGR — compounding case rests on the competitive position widening. 10 yr $1,029 if current growth sustains into durable earnings power.
5. NBIX — Neurocrine Biosciences, Inc. · score 87
Drug Manufacturers - Specialty & Generic · price $179.05 · 1Y $200.24 · 5Y $293.17 · 10Y $434.89
FCF $831m C+ · Rev +28.6% A- · D/E 0.14 B+ · P/E 27.5x B · PEG 0.48 A
Why now. NBIX is a high‑growth compounder anchored by its market‑leading INGREZZA and Orilissa franchises, which are driving a 28.6% YoY revenue surge and a 21.6% profit margin. Our Bull Rankings model awards a Quality‑Growth score of 87 with Growth as the strongest pillar, underscoring the durability of its pipeline‑driven expansion, while the modest PEG of 0.48 signals that the market still under‑prices this trajectory. The thesis rests on continued compounding from these products and the pipeline, which the reverse‑DCF’s implied 13% FCF growth comfortably supports.
Moat. NBIX’s moat stems from its FDA‑approved, niche‑indication drugs—INGREZZA for tardive dyskinesia and Orilissa for endometriosis—where switching costs are high due to specialized dosing and limited alternatives, delivering a ROE of 19.6% that reflects pricing power in these underserved markets.
Risk. The bear case hinges on the risk that upcoming competitors could erode the market share of INGREZZA and Orilissa, while the stock trades at a premium PE of 27.5 that may not be justified if revenue growth decelerates below the historic 28.6% rate. A slowdown in new product approvals would trigger a price correction, confirming the downside.
Horizon. 1-3 yr $200.24 (analyst consensus (n=28)) — fundamentals + valuation re-rating. 5 yr $293.17 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $434.89 if current growth sustains into durable earnings power.
6. LRN — Stride, Inc. · score 86.8
Education & Training Services · price $84.69 · 1Y $97.39 · 5Y $142.59 · 10Y $211.53
FCF $414m C · Rev +10.9% B · D/E 0.33 A- · P/E 13.3x A- · PEG 0.49 A
Why now. Stride’s integrated virtual‑school platform is rapidly becoming the go‑to solution for districts expanding blended learning, and that stickiness fuels a compounding engine. The business is delivering 10.9% YoY revenue growth, 12.2% profit margin and $414 m of free cash flow while trading at a modest PE of 13.3x, all of which sit under the Bull Rankings model’s strongest pillar – Value – giving the stock a clear upside catalyst. The thesis rests on the continuation of this high‑margin, cash‑generating growth in the online‑curriculum market.
Moat. Stride’s moat lies in its end‑to‑end suite of curriculum, enrollment and progress‑tracking software that locks schools into a single data ecosystem, creating high switching costs for districts that have built multi‑year contracts and integrated student data. The 18.8% ROE reflects pricing power derived from being the only provider that bundles curriculum with the full school‑operations stack, a capability competitors can’t replicate quickly.
Risk. The bear case centers on the modest quality score (80) signaling that the business may lack the defensive depth of peers; a PE of 13.3x, while low, still embeds expectations of sustained growth that could falter if district budgets tighten, and the debt‑to‑equity of 0.33 leaves limited headroom for further leverage. A slowdown in FY revenue growth below the current 10.9% would trigger a sell‑off, confirming the risk.
Horizon. 1-3 yr $97.39 (structural (no analyst coverage)) — fundamentals + valuation re-rating. 5 yr $142.59 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $211.53 if current growth sustains into durable earnings power.
7. NVDA — NVIDIA Corporation · score 86.5
Semiconductors · price $207.29 · 1Y $302.31 · 5Y $442.61 · 10Y $656.59
FCF $119.1b A · Rev +70.7% A · D/E 0.07 A- · P/E 31.7x B · PEG 0.56 A-
Why now. The bull case hinges on NVIDIA’s Compute & Networking segment exploding as AI‑driven data‑center demand surges, delivering 70.7% FY YoY revenue growth, 63% profit margin, and a $119.1B free‑cash‑flow runway that fuels both R&D and buybacks. Our model’s 86.5/100 quality‑growth score, led by a perfect Growth pillar, underscores that this compounding engine will keep accelerating as enterprises double‑down on AI acceleration.
Moat. NVIDIA’s moat stems from its GPU architecture that powers the majority of AI workloads, locking in data‑center customers who face massive switching costs and benefit from NVIDIA’s proprietary software stack. The 81.7% ROE reflects pricing power derived from being the de‑facto standard in high‑performance compute, a position rivals can’t replicate without years of R&D and ecosystem building.
Risk. The bear case centers on the lofty 31.7 P/E and a beta of 2.21, suggesting the stock is over‑priced if AI spending slows or competitors like AMD catch up in GPU performance, which would compress margins. A breakout of the 52‑week low at $164.07 or a slowdown in free‑cash‑flow growth would confirm the valuation is unsustainable and could trigger a sharp correction.
Horizon. 1-3 yr $302.31 (analyst consensus (n=58)) — fundamentals + valuation re-rating. 5 yr $442.61 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $656.59 if current growth sustains into durable earnings power.
8. TTD — The Trade Desk, Inc. · score 85.6
Advertising Agencies · price $18.25 · 1Y $24.32 · 5Y $35.61 · 10Y $52.82
FCF $842m C+ · Rev +15.5% B+ · D/E 0.17 A- · P/E 20.7x B · PEG 0.89 B+
Why now. The Trade Desk’s programmatic platform for CTV and video ads is the engine of its next growth wave, delivering 15.5% YoY revenue growth, a healthy 14.6% profit margin and a free‑cash‑flow haul of $842 m on an $8.6 b market cap. Our Bull Rankings model flags Growth as the strongest pillar (93), meaning the business can keep compounding as advertisers shift spend to addressable, cross‑device inventory. The thesis hinges on the platform’s ability to capture ever‑larger slices of the digital ad spend market, turning that secular tailwind into sustained earnings expansion.
Moat. TTD’s moat lives in its data‑rich, self‑serve buying platform that agencies and brands embed into their media stacks, creating high switching costs and network effects as more spend fuels richer audience insights. The 17.6% ROE reflects pricing power derived from being the go‑to technology for premium CTV inventory, a segment rivals can’t replicate quickly without comparable data assets and integration depth.
Risk. The stock trades at a forward P/E of 20.7 and a PEG of 0.89, implying the market already prices in aggressive growth; our reverse DCF shows the current price assumes a -5% annual FCF decline, a stark mismatch to the 15.5% revenue growth reality. A slowdown in ad spend or a win by a rival platform would force the valuation down, and a breach of the 52‑week low ($16.98) would signal that the optimism was misplaced. The bear case is confirmed if quarterly revenue growth dips below 10% and the price slides back toward that low.
Horizon. 1-3 yr $24.32 (analyst consensus (n=30)) — fundamentals + valuation re-rating. 5 yr $35.61 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $52.82 if current growth sustains into durable earnings power.
9. EXLS — ExlService Holdings, Inc. · score 85.5
Information Technology Services · price $27.35 · 1Y $40.13 · 5Y $58.75 · 10Y $87.15
FCF $297m C · Rev +13.4% B+ · D/E 0.67 C+ · P/E 17.4x A- · PEG 0.90 B+
Why now. The Bull Rankings model gives EXLS an 85.5 Quality‑Growth score, with Growth as its strongest pillar, because its AI‑enabled insurance operations are expanding at 13.4% YoY revenue growth while delivering 11.7% profit margins and a stellar 32.3% ROE. That combination of high‑margin cash generation ($297 m FCF) and a low PEG of 0.9 means earnings are set to compound well beyond the market’s modest 1% implied FCF growth, making the stock a premium growth play.
Moat. EXLS’s moat lives in its AI‑driven claims management, underwriting support and policy servicing platform that locks insurers into a data‑intensive workflow, creating high switching costs and pricing power that fuels its 32.3% ROE. The integrated analytics across Insurance, Healthcare and Banking sectors deepen client relationships, turning each contract into a long‑term revenue stream that competitors can’t replicate quickly.
Risk. The bear case hinges on the reverse‑DCF showing the market pricing in a negative -1% annual FCF growth for the next decade, a stark contrast to the current 13.4% revenue expansion; if growth stalls or margins compress, the 17.4 P/E becomes stretched for a company with a 0.67 debt‑to‑equity ratio that could limit buyback flexibility. A slowdown in insurance spend or a disruptive AI entrant would force the stock below the 52‑week low of $24.85, confirming the downside.
Horizon. 1-3 yr $40.13 (analyst consensus (n=8)) — fundamentals + valuation re-rating. 5 yr $58.75 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $87.15 if current growth sustains into durable earnings power.
10. HRMY — Harmony Biosciences Holdings, Inc. · score 85
Biotechnology · price $36.84 · 1Y $44.91 · 5Y $65.75 · 10Y $97.54
FCF $342m C · Rev +20.7% A- · D/E 0.18 B+ · P/E 14.9x A- · PEG 0.69 A-
Why now. HRMY's WAKIX, the only FDA‑approved therapy for narcolepsy‑related excessive daytime sleepiness, is poised to dominate a rapidly expanding rare‑neurology market, driving compounding revenue at 20.7% YoY while preserving a healthy 16.2% profit margin. The stock trades at a modest PE of 14.9 and a sub‑1.0 PEG of 0.69, indicating ample room for earnings acceleration as Phase 3 and Phase 2 trials mature. The entire thesis hinges on WAKIX’s continued market share gains and pipeline de‑risking delivering sustained top‑line growth.
Moat. WAKIX’s novel mechanism of action and exclusive U.S. commercial rights give HRMY a protected foothold in the rare neurological space, creating high switching costs for patients and physicians. The company’s 16% ROE stems from pricing power and efficient cost structure tied to a focused product portfolio, while its low 0.18 debt‑to‑equity ratio limits financial risk, reinforcing the durability of its earnings moat.
Risk. HRMY remains heavily dependent on WAKIX; any regulatory setback or competitive launch could compress its 14.9 P/E and stall the 20.7% revenue growth, while the reverse‑DCF shows the market already assumes a -18% annual free‑cash‑flow decline—if cash flow turns negative, the stock could tumble. A failure in the Phase 3 Prader‑Willi or Phase 2 myotonic dystrophy trials would confirm the bear case and erode the growth narrative.
Horizon. 1-3 yr $44.91 (analyst consensus (n=11)) — fundamentals + valuation re-rating. 5 yr $65.75 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $97.54 if current growth sustains into durable earnings power.
11. ADMA — ADMA Biologics, Inc. · score 84.7
Biotechnology · price $8.59 · 1Y $17.00 · 5Y $24.89 · 10Y $36.92
FCF $108m C · Rev +11.0% B · D/E 1.11 C · P/E 12.6x A · PEG 0.64 A-
Why now. ADMA’s ASCENIV IVIG franchise is poised to dominate the U.S. primary immunodeficiency market, driving compounding earnings as the patient base expands. The business is already delivering 32.4% profit margin, 42.4% ROE and 11% revenue growth YoY, while the Bull Rankings model flags Growth as its strongest pillar (90) and a reverse‑DCF implies only ~3% FCF growth—far below the real earnings trajectory, meaning the market is under‑pricing the compounding power. The thesis rests on sustained IVIG demand and the ability to reinvest cash into share buybacks that amplify returns.
Moat. ADMA controls the entire plasma‑to‑product chain through its ADMA BioManufacturing and Plasma Collection Centers, creating a high‑cost barrier for new entrants and locking in hospitals that require consistent, FDA‑approved IVIG supplies. Its ROE of 42.4% stems from pricing power in a niche, life‑saving biologics category where switching patients incurs clinical risk, giving ADMA a durable pricing advantage.
Risk. The stock trades at a steep discount to its 52‑week high of $20.46, reflecting market skepticism that the current PE of 12.6 already embeds optimism; a slowdown in IVIG adoption or a rise in the debt‑to‑equity ratio (now 1.11) could force the price back toward the low‑end, confirming the bear case. A breach of the debt ceiling or a failure to sustain margin expansion would invalidate the growth narrative.
Horizon. 1-3 yr $17.00 (analyst consensus (n=5)) — fundamentals + valuation re-rating. 5 yr $24.89 at ~24% CAGR — compounding case rests on the competitive position widening. 10 yr $36.92 if current growth sustains into durable earnings power.
12. PRDO — Perdoceo Education Corporation · score 84.1
Education & Training Services · price $30.51 · 1Y $35.09 · 5Y $51.37 · 10Y $76.20
FCF $225m C · Rev +17.7% B+ · D/E 0.12 A- · P/E 11.6x A- · PEG 0.68 A-
Why now. The Bull Rankings model gives PRDO a Quality‑growth score of 84.1 anchored by a Quality pillar of 89, and the core thesis is that its Colorado Technical University (CTU) segment will keep compounding revenue at 17.7% YoY while converting that into a 19.9% profit margin. The online, career‑oriented programs in high‑growth fields like cybersecurity and nursing drive a free‑cash‑flow runway of $225 m and support a cheap PE of 11.6x. The whole case rests on the ability of CTU’s niche enrollment pipeline to sustain the 17‑plus % growth rate for years to come.
Moat. PRDO’s moat comes from its vertically integrated delivery of blended and fully online programs that lock in students through tuition‑based financing and industry‑aligned curricula, especially in CTU’s nursing and cybersecurity tracks. This creates high switching costs for students who have already invested in credits and certifications, while the low‑debt balance sheet (Debt/Equity 0.12) lets the company reinvest cash into technology and marketing without diluting shareholders.
Risk. The bear case is that the implied -16% annual free‑cash‑flow growth in our reverse‑DCF is wildly optimistic; if enrollment slows or margin pressure rises, the current PE of 11.6x could quickly turn into a valuation trap. A modest deceleration to low‑single‑digit revenue growth would cut FCF dramatically, and a breach of the 0.12 debt‑to‑equity ceiling would signal rising leverage. The key risk trigger is a quarterly enrollment miss that pushes revenue growth below the current trajectory, eroding the compounding narrative.
Horizon. 1-3 yr $35.09 (structural (no analyst coverage)) — fundamentals + valuation re-rating. 5 yr $51.37 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $76.20 if current growth sustains into durable earnings power.
13. CARG — CarGurus, Inc. · score 83.3
Auto & Truck Dealerships · price $35.06 · 1Y $37.38 · 5Y $54.73 · 10Y $81.20
FCF $293m C · Rev +14.0% B+ · D/E 0.79 B · P/E 18.5x B+ · PEG 1.06 B+
Why now. CarGurus’ Digital Deal platform is unlocking a new, high‑margin revenue stream that fuels its 14% FY YoY revenue growth, while its dealer subscription model delivers a rock‑solid 15.9% profit margin and a staggering 62.9% ROE. The Bull Rankings model awards the stock an 83.3/100 quality‑growth score—its strongest pillar, Quality, reflects the durable dealer network and pricing power, and the thesis hinges on the continued expansion of Digital Deal and subscription fees compounding earnings year after year.
Moat. The moat lives in CarGurus’ integrated dealer ecosystem: thousands of dealers pay subscription fees to access a captive audience of car shoppers, creating a high‑switching‑cost relationship that locks in recurring revenue. This network, combined with the company’s ability to monetize listings through Digital Deal, translates the impressive 62.9% ROE into sustainable pricing power that rivals can’t replicate without rebuilding the same dealer‑buyer lattice.
Risk. The stock trades at an elevated 18.5× PE and a beta of 1.18, while the Bull Rankings model flags Value as its weakest pillar, signaling that the market may be over‑paying for growth. Moreover, the reverse DCF implies a -1% annual free‑cash‑flow growth, starkly at odds with the 14% revenue expansion—any slowdown in Digital Deal adoption or a rise in debt‑to‑equity (0.79) could force the price below the 52‑week low of $26.39, confirming the bear case.
Horizon. 1-3 yr $37.38 (analyst consensus (n=13)) — fundamentals + valuation re-rating. 5 yr $54.73 at ~9% CAGR — compounding case rests on the competitive position widening. 10 yr $81.20 if current growth sustains into durable earnings power.
14. RMD — ResMed Inc. · score 83.1
Medical Instruments & Supplies · price $195.80 · 1Y $248.73 · 5Y $364.17 · 10Y $540.22
FCF $1.8b C+ · Rev +10.3% B · D/E 0.13 B+ · P/E 18.9x A- · PEG 1.18 B+
Why now. ResMed’s cloud‑connected sleep‑diagnostic platform – anchored by devices like ApneaLink Air and the disposable NightOwl – is locking in high‑margin recurring revenue, as evidenced by 10.3% revenue growth YoY, a 27.4% profit margin, and a 23.4% ROE. Our Bull Rankings model awards the stock an 83.1 quality‑growth score, with Quality as its strongest pillar, underscoring the durable competitive edge of its integrated hardware‑software ecosystem. The thesis hinges on that ecosystem continuing to compound earnings faster than the market’s modest 1% reverse‑DCF growth assumption.
Moat. The combined hardware and cloud‑software suite creates a high switching cost for sleep clinics, hospitals and home‑care providers, cementing ResMed’s position as the go‑to supplier for apnea diagnosis and therapy. This lock‑in fuels the 23.4% ROE, reflecting pricing power derived from category leadership in both the Sleep and Breathing Health segment and the Residential Care Software platform.
Risk. The market is pricing ResMed for near‑term optimism: a forward P/E of 18.9 vastly exceeds the 1% annual free‑cash‑flow growth implied by our reverse DCF, while revenue growth has slowed to just 10.3% YoY. Any deceleration in device adoption or a shift to lower‑margin software contracts would compress margins and could see the stock retreat toward its 52‑week low of $180.27. A sustained miss on growth would validate the bear case.
Horizon. 1-3 yr $248.73 (analyst consensus (n=15)) — fundamentals + valuation re-rating. 5 yr $364.17 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $540.22 if current growth sustains into durable earnings power.
15. EPAM — EPAM Systems, Inc. · score 83
Information Technology Services · price $89.22 · 1Y $135.94 · 5Y $199.03 · 10Y $295.25
FCF $544m C+ · Rev +14.2% B+ · D/E 0.08 B+ · P/E 12.8x A- · PEG 0.46 A
Why now. EPAM’s digital platform engineering and cloud services are rapidly becoming the backbone for Fortune‑500 enterprises seeking end‑to‑end automation, driving a 14.2% YoY revenue growth and generating $544 m of free cash flow on a modest PE of 12.8. Our Bull Rankings model awards a Quality‑Growth score of 83, with Value as the strongest pillar, underscoring the stock’s cheapness relative to its growth trajectory. The reverse‑DCF shows the market is assuming a negative 3% FCF growth, far below the actual growth rate, leaving ample upside if the company sustains its current momentum.
Moat. EPAM’s moat lies in its integrated engineering‑to‑operations platform, which locks in large enterprise clients through deep customization, cross‑platform migration, and smart‑automation services that are costly to replicate. This high switching cost, combined with a low debt‑to‑equity of 0.08, lets the firm reinvest cash into proprietary tools and maintain a steady ROE of 11.3% driven by pricing power in high‑margin cloud and AI projects.
Risk. The stock’s 1.43 beta and a PEG of 0.46 signal that any slowdown in revenue growth or a margin squeeze could quickly erode returns, especially as our model flags Quality as the weakest pillar (72). A pullback in enterprise IT spend or a successful competitor’s low‑cost cloud offering would force EPAM’s margins lower, confirming the bear case if the price falls toward its 52‑week low of $73.06.
Horizon. 1-3 yr $135.94 (analyst consensus (n=17)) — fundamentals + valuation re-rating. 5 yr $199.03 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $295.25 if current growth sustains into durable earnings power.
16. DXCM — DexCom, Inc. · score 82.3
Medical Devices · price $74.75 · 1Y $85.75 · 5Y $125.55 · 10Y $186.24
FCF $1.4b C+ · Rev +16.1% B+ · D/E 0.47 B · P/E 32.1x C+ · PEG 1.43 B
Why now. The bull case hinges on DexCom’s G7 platform cementing its lead in the U.S. CGM market, driving a revenue compound that still runs 16.1% YoY while delivering a 19.3% profit margin and a stellar 31.5% ROE. Our Bull Rankings model awards a Growth pillar of 96, confirming that the business is a high‑quality compounder, and the consensus 1‑yr target of $85.75 already reflects near‑term upside from expanding G7 adoption and the new 15‑day sensor rollout. The thesis rests on continued market share gains in the diabetes‑management segment, which should keep the compounding engine humming.
Moat. DexCom’s moat derives from its integrated G7 system and the Dexcom Share remote‑monitoring network, which lock in endocrinologists and patients through a proprietary sensor‑app ecosystem that is hard to replicate. The 31.5% ROE is underpinned by pricing power that stems from being the clinical standard for continuous glucose monitoring, forcing competitors to overcome both regulatory hurdles and entrenched physician relationships.
Risk. The bear case centers on the lofty valuation: a forward P/E of 32.1 and a beta of 1.45 signal that the market is pricing in aggressive growth, while our model’s Value pillar is only 66, flagging a potential over‑pay. If the implied 19% free‑cash‑flow growth over the next decade proves unrealistic versus the current 16.1% revenue growth, the stock could tumble toward its 52‑week low of $54.11. A slowdown in G7 adoption or a successful competitor launch would confirm this risk.
Horizon. 1-3 yr $85.75 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $125.55 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $186.24 if current growth sustains into durable earnings power.
17. VEEV — Veeva Systems Inc. · score 82.1
Health Information Services · price $189.24 · 1Y $244.59 · 5Y $358.11 · 10Y $531.23
FCF $1.7b C+ · Rev +16.2% B+ · D/E 0.01 A- · P/E 33.5x C+ · PEG 0.88 B+
Why now. Veeva’s Veeva Commercial Cloud, anchored by the Vault CRM Suite, is winning the pharma‑tech race as life‑science firms double‑down on cloud‑first strategies, driving 16.2% revenue growth and a 28.4% profit margin. Our Bull Rankings model awards the company an 82.1 Quality‑Growth score, with Growth as the strongest pillar (94) and Value the weakest, underscoring that the upside lives in the compounding power of its high‑margin SaaS franchise. The stock already embeds a 7% free‑cash‑flow growth assumption, but the 16% top‑line expansion suggests the price is still discounting the full upside, making the compounding of SaaS ARR the core thesis.
Moat. The Vault CRM Suite locks in pharmaceutical and biotech customers through deep integration with regulated data, creating switching costs that are hard to replicate without extensive compliance certifications. This stickiness fuels a ROE of 12.9%, reflecting pricing power from category leadership in the life‑sciences cloud market, while the near‑zero debt‑to‑equity (0.01) gives Veeva financial flexibility to reinvest in product innovation.
Risk. The bull case hinges on continued SaaS adoption, but a P/E of 33.5 signals that the market is already pricing in premium growth; any slowdown in the 16.2% revenue trajectory or margin compression would expose the valuation gap. A bear signal would be a breach of the 52‑week low at $148.05, which would force a re‑rating of the implied 7% FCF growth to a more modest pace and erode the growth premium.
Horizon. 1-3 yr $244.59 (analyst consensus (n=27)) — fundamentals + valuation re-rating. 5 yr $358.11 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $531.23 if current growth sustains into durable earnings power.
18. ACN — Accenture plc · score 81.2
Information Technology Services · price $140.86 · 1Y $178.89 · 5Y $261.91 · 10Y $388.53
FCF $12.6b A- · Rev +6.7% C+ · D/E 0.25 B · P/E 11.3x A · PEG 1.04 B+
Why now. Accenture’s dominance in AI‑enabled cloud and intelligent platform services is the engine that will keep earnings compounding, because its 6.7% revenue growth is backed by a massive $12.6B free‑cash‑flow generation base and a rock‑solid PE of 11.3x that leaves ample headroom for margin expansion. The firm’s ability to lock in multi‑year digital transformation contracts across finance, supply‑chain and HR functions means the growth engine is repeatable and hard to displace. The whole thesis rests on the persistence of this high‑margin, high‑growth consulting‑to‑cloud flywheel.
Moat. Accenture’s end‑to‑end delivery model—spanning strategy, systems integration, security and managed services—creates a switching cost that few rivals can match, especially for large enterprises that need a single trusted partner for finance, procurement and AI‑driven analytics. Its ROE of 24.4% reflects pricing power derived from category leadership in digital transformation, allowing it to command premium fees while leveraging a global delivery network that scales cost‑effectively.
Risk. The Bull Rankings model’s reverse‑DCF shows the current price embeds a -13% annual free‑cash‑flow growth rate for the next decade, a stark mismatch to the actual 6.7% revenue growth and suggests the market is over‑optimistic about future compounding; any slowdown in cloud or AI spend would force the valuation down. A bear‑case trigger would be a sustained dip in revenue growth below 4% combined with margin compression, which would validate the overly lofty growth assumptions baked into the price.
Horizon. 1-3 yr $178.89 (analyst consensus (n=25)) — fundamentals + valuation re-rating. 5 yr $261.91 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $388.53 if current growth sustains into durable earnings power.
19. APP — AppLovin Corporation · score 80.5
Advertising Agencies · price $428.69 · 1Y $654.60 · 5Y $958.40 · 10Y $1,422
FCF $4.4b B · Rev +66.4% A · D/E 1.63 C · P/E 37.2x C+ · PEG 1.17 B+
Why now. AppLovin’s AI‑driven MAX in‑app bidding platform is unlocking explosive revenue compounding, as evidenced by 66.4% YoY revenue growth, a staggering 64.3% profit margin, and $4.4 B of free cash flow that fuels reinvestment. Our Bull Rankings model flags Growth as the strongest pillar (score 98) and the 80.5 overall quality‑growth rating, underscoring that the business’s high‑margin engine can keep compounding faster than peers. The thesis rests on the persistence of in‑app auction economics that continue to scale with mobile ad spend.
Moat. MAX creates a network effect for publishers: each additional app adds inventory to the real‑time auction, raising the value of the platform for advertisers and locking in publishers who would lose auction efficiency by switching. Coupled with Adjust’s measurement suite, AppLovin offers an end‑to‑end stack that raises switching costs for both developers and brands, protecting its high‑margin advantage.
Risk. The stock trades at a lofty PE of 37.2 and a beta of 2.48, implying market expectations far above the historic growth rate; a slowdown in mobile ad spend or a successful rival bidding solution could compress margins and force the price toward the 52‑week low of $343. A breach of the 1.63 debt‑to‑equity ratio with higher leverage would confirm the bear case and invalidate the growth narrative.
Horizon. 1-3 yr $654.60 (analyst consensus (n=30)) — fundamentals + valuation re-rating. 5 yr $958.40 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $1,422 if current growth sustains into durable earnings power.
20. META — Meta Platforms, Inc. · score 79.6
Internet Content & Information · price $643.81 · 1Y $822.69 · 5Y $1,204 · 10Y $1,787
FCF $48.3b A · Rev +26.2% A- · D/E 0.36 B+ · P/E 23.4x B · PEG 0.94 B+
Why now. Meta’s explosive 26.2% YoY revenue growth in its Family of Apps fuels a compounding engine that the Bull Rankings model flags as its strongest pillar – Growth – and the market has already priced in with a lofty 29% annual free‑cash‑flow growth assumption from the reverse‑DCF. Coupled with a razor‑thin 32.8% profit margin and a 29% ROE, the platform’s ad‑driven cash machine can keep reinvesting in AI‑enhanced feeds and Reels, driving the next wave of user engagement. The thesis rests on the FoA segment’s ability to sustain this high‑margin growth trajectory.
Moat. Meta’s moat lives in the network‑effect of its Family of Apps – Facebook, Instagram, and Messenger – where billions of users generate data that fuels ever‑more effective ad targeting, creating a barrier that rivals cannot replicate quickly. The 29% ROE stems from pricing power in a category‑lead ad market where advertisers pay premium CPMs for access to this locked‑in audience, reinforcing cash returns and funding the Reality Labs push without eroding margins.
Risk. The bear case centers on the market’s expectation of a 29% FCF growth rate that vastly outpaces the actual 26.2% revenue growth, implying a valuation stretch given the current P/E of 23.4 and a beta of 1.25 that amplifies downside in a volatile tech environment. A slowdown in ad spend or a shift to competing platforms would compress margins and force the price toward the 52‑week low of $520.26, confirming the over‑optimism.
Horizon. 1-3 yr $822.69 (analyst consensus (n=58)) — fundamentals + valuation re-rating. 5 yr $1,204 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $1,787 if current growth sustains into durable earnings power.
21. MELI — MercadoLibre, Inc. · score 79.5
Internet Retail · price $1822.65 · 1Y $2,215 · 5Y $3,243 · 10Y $4,810
FCF $11.8b A- · Rev +36.4% A · D/E 1.70 C+ · P/E 48.1x C · PEG 1.12 B+
Why now. The bull case hinges on MercadoLibre’s dominant Marketplace and the explosive growth of Mercado Pago, which is fueling a 36.4% revenue growth YoY and generating $11.8 B of free cash flow. Our Bull Rankings model awards MELI a Quality‑Growth score of 79.5, with Growth as the strongest pillar, underscoring the durability of its high‑velocity e‑commerce and fintech tailwinds. The combination of a 26.4% ROE and a $92.4 B market cap at a modest PE of 48.1 still leaves ample room for compounding as the Latin American e‑commerce market expands, making the growth engine the single driver of upside.
Moat. MELI’s moat stems from the seamless integration of its Marketplace with Mercado Pago, creating a two‑sided network where sellers and buyers are locked into a single payments and logistics ecosystem. This integration yields high pricing power and a ROE of 26.4%, as merchants pay premium fees for the convenience and trust of a unified platform that competitors cannot replicate quickly without building both commerce and fintech layers from scratch.
Risk. The bear case focuses on the lofty valuation: a PE of 48.1 and a reverse‑DCF implied free‑cash‑flow growth of –7% per year signal that the market is already pricing in aggressive future performance. Any slowdown in the 36.4% revenue growth trajectory or a rise in the debt‑to‑equity ratio of 1.7 would pressure margins and could trigger a sharp correction, especially given the beta of 1.34 that amplifies market volatility. A breach of the 52‑week low ($1,495) would confirm the over‑optimism and invalidate the growth thesis.
Horizon. 1-3 yr $2,215 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $3,243 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $4,810 if current growth sustains into durable earnings power.
22. PODD — Insulet Corporation · score 79
Medical Devices · price $163.72 · 1Y $238.22 · 5Y $348.77 · 10Y $517.38
FCF $416m C · Rev +31.9% A · D/E 0.78 C+ · P/E 38.3x C+ · PEG 1.45 B
Why now. The Omnipod 5 automated insulin delivery system is unlocking a new wave of adoption as insurers expand coverage for hybrid closed‑loop therapy, and Insulet’s 31.9% FY revenue growth validates that momentum. Coupled with a 10.4% profit margin and $416 m of free cash flow, the business is compounding earnings at a rate that our model flags as a 100‑point Growth pillar (79/100 overall). The thesis hinges on sustained AID adoption driving double‑digit top‑line expansion for years to come.
Moat. Insulet’s pod‑based platform creates a hard switching cost: the Omnipod 5 embeds a proprietary algorithm and Bluetooth integration that require a dedicated pod and manager, locking patients into the ecosystem. This lock‑in, combined with a ROE of 23.2% derived from pricing power as the market leader in tubeless insulin pumps, underpins durable profitability.
Risk. The premium price of the Omnipod system forces a P/E of 38.3, far above sector averages, and any slowdown in reimbursement or a successful launch of a lower‑cost competitor could compress margins. A debt‑to‑equity of 0.78 also signals rising leverage that would hurt cash flow if growth decelerates. A breach of the 10.4% profit margin would confirm the bear case.
Horizon. 1-3 yr $238.22 (analyst consensus (n=23)) — fundamentals + valuation re-rating. 5 yr $348.77 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $517.38 if current growth sustains into durable earnings power.
23. NFLX — Netflix, Inc. · score 78.8
Entertainment · price $68.67 · 1Y $97.70 · 5Y $143.05 · 10Y $212.20
FCF $11.2b A- · Rev +16.0% B+ · D/E 0.55 B · P/E 21.6x B · PEG 1.35 B
Why now. Netflix’s global streaming platform continues to compound subscriber revenue, driven by its ever‑expanding library of TV series, documentaries, feature films and games that reach members on every internet‑connected device. The business is delivering 16% YoY revenue growth, a 28.2% profit margin and a staggering 45.3% ROE, all while trading at a modest PE of 21.6x. The Bull Rankings model rates its Quality at 92 – the highest pillar – confirming that the cash‑generating engine is hard to displace, and the thesis rests on the relentless compounding of streaming cash flow.
Moat. The moat lives in Netflix’s proprietary content ecosystem and its seamless distribution across TVs, set‑top boxes and mobile devices, creating a high‑switching‑cost subscription base. Its 45.3% ROE stems from pricing power as the market leader in on‑demand streaming, allowing it to raise subscription fees faster than peers without losing members. This content‑distribution lock‑in fuels durable free‑cash‑flow generation.
Risk. The bear case centers on the premium valuation and competitive pressure: a PE of 21.6x is high for a growth name, while the Bull Rankings model flags Value at only 59, indicating the price already embeds aggressive expectations. Beta of 1.52 amplifies market volatility, and a debt‑to‑equity of 0.55 could constrain cash flow if content spend spikes. A sustained slowdown in revenue growth below the 16% trend would validate the over‑optimism and trigger a sharp correction.
Horizon. 1-3 yr $97.70 (analyst consensus (n=44)) — fundamentals + valuation re-rating. 5 yr $143.05 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $212.20 if current growth sustains into durable earnings power.
24. DECK — Deckers Outdoor Corporation · score 78.4
Footwear & Accessories · price $103.31 · 1Y $127.81 · 5Y $187.13 · 10Y $277.59
FCF $1.1b C+ · Rev +9.8% B · D/E 0.15 A · P/E 14.7x A- · PEG 1.33 B
Why now. Deckers' HOKA performance‑running franchise is the engine of growth, delivering 9.8% YoY revenue expansion and fueling a 18.7% profit margin that translates into $1.1 B of free cash flow. Coupled with a stellar ROE of 41% and a quality‑growth score of 78.4 (Quality pillar 96), the company is compounding earnings at a pace few peers can match. The thesis hinges on HOKA’s continued premium pricing power and the upside from ongoing share buybacks.
Moat. Deckers locks in margin advantage through HOKA’s differentiated performance technology and UGG’s entrenched lifestyle cachet, allowing it to command premium prices that drive the 41% ROE. Its multi‑brand distribution network—spanning specialty retailers to direct‑to‑consumer channels—creates high switching costs for consumers who blend performance and lifestyle footwear, a mix competitors struggle to replicate quickly.
Risk. The Bull Rankings model flags a weak Value pillar (60) and a reverse‑DCF implied FCF growth of only ~3%/yr, far below the 9.8% revenue growth, suggesting the market may be over‑optimistic about future cash generation. A slowdown in premium footwear demand or a pricing squeeze would compress the 18.7% margin, and with a beta of 1.17 the stock is vulnerable to broader market volatility. A sustained miss on margin or growth would validate the bearish view.
Horizon. 1-3 yr $127.81 (analyst consensus (n=21)) — fundamentals + valuation re-rating. 5 yr $187.13 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $277.59 if current growth sustains into durable earnings power.
25. FIVE — Five Below, Inc. · score 78
Specialty Retail · price $203.71 · 1Y $260.33 · 5Y $381.15 · 10Y $565.42
FCF $505m C+ · Rev +25.9% A- · D/E 0.86 B · P/E 25.7x C+ · PEG 0.98 B+
Why now. The Bull Rankings model gives Five Below a Quality‑Growth score of 78, with Growth as its strongest pillar, because the retailer is exploding in the teen‑and‑young‑adult value segment – its ever‑refreshing candy, novelty and seasonal merch drives a 25.9% YoY revenue growth, a 8.7% profit margin and a 19% ROE. Those fundamentals underpin a 13% FCF‑growth assumption baked into today’s price, meaning the stock already reflects aggressive optimism, but the compounding power of its low‑price, high‑turnover assortment still leaves upside. The thesis rests on sustaining that growth cycle as the core customer base expands.
Moat. Five Below’s moat lies in its curated, low‑price assortment that captures the impulse spend of Gen Z shoppers who crave novelty candy, trendy accessories and seasonal décor – a mix that is hard for big‑box rivals to replicate at the same price point. This product‑mix yields a 19% ROE, reflecting pricing power and efficient inventory turnover that translate into consistent free cash flow of $505 m.
Risk. The bear case centers on the premium valuation: a forward P/E of 25.7 and a PEG of 0.98 imply the market expects growth to outpace earnings, yet any slowdown from the current 25.9% revenue surge would compress margins that are only 8.7% today. A debt‑to‑equity of 0.86 adds leverage risk, and a beta of 1 means the stock moves with the market, so a broader retail pullback could knock the price back toward its 52‑week low of $130. A missed revenue target would confirm the over‑optimism and trigger a sell‑off.
Horizon. 1-3 yr $260.33 (analyst consensus (n=21)) — fundamentals + valuation re-rating. 5 yr $381.15 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $565.42 if current growth sustains into durable earnings power.
26. CRDO — Credo Technology Group Holding Ltd · score 76.8
Semiconductors · price $223.87 · 1Y $278.50 · 5Y $407.75 · 10Y $604.87
FCF $407m C · Rev +205.7% A · D/E 0.01 A · P/E 89.5x C · PEG 0.44 A
Why now. Credo’s explosive 205.7% YoY revenue growth is being driven by its ZeroFlap (ZF) active electrical cables and optical transceivers, which dominate the high‑speed Ethernet and PCIe markets for hyperscale data‑center customers. Coupled with a razor‑thin 35.4% profit margin and a stellar 22.9% ROE, the company is a high‑quality compounder that can keep compounding as data‑center bandwidth demand accelerates. The thesis rests on the continuation of this growth engine.
Moat. Credo protects its advantage through proprietary SerDes IP licensing and a vertically integrated portfolio of active cables, transceivers, and retimers that lock in customers with high switching costs and strict performance specifications. This IP moat, combined with its ability to command premium pricing—evidenced by a ROE near 23%—makes it difficult for generic competitors to replicate the solution stack quickly.
Risk. The stock trades at an eye‑watering PE of 89.5 and a beta of 3.2, meaning any market pull‑back or slowdown in data‑center capex could slam the valuation. Our model flags diluting shareholders, and a breach of the dilution signal would erode EPS and validate the high‑multiple risk. A sustained drop in revenue growth or a widening of the PE gap would confirm the bear case.
Horizon. 1-3 yr $278.50 (analyst consensus (n=19)) — fundamentals + valuation re-rating. 5 yr $407.75 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $604.87 if current growth sustains into durable earnings power.
27. YUMC — Yum China Holdings, Inc. · score 76.3
Restaurants · price $42.77 · 1Y $61.34 · 5Y $89.81 · 10Y $133.23
FCF $931m C+ · Rev +6.7% C+ · D/E 0.38 A- · P/E 16.4x B+ · PEG 1.10 B+
Why now. Yum China’s KFC and Pizza Hut brands dominate fast‑food dining in China, and the company’s online food‑delivery platform is scaling alongside that footprint. The business delivers 7.8% profit margins, generates $931 m of free cash flow and trades at a modest PE of 16.4× while the Bull Rankings model rates its Quality pillar at 83 – the highest among peers – giving confidence that earnings are sustainable. The thesis rests on the ability to compound the 6.7% YoY revenue growth into a multi‑year cash‑flow engine that outpaces the model’s implied 5% DCF growth.
Moat. Yum China’s moat comes from its entrenched KFC and Pizza Hut restaurant network that serves millions of urban diners daily, coupled with a proprietary delivery logistics platform that locks in repeat orders and limits new entrants’ ability to win market share. The franchise‑heavy model yields a 17.4% ROE, reflecting pricing power and cost efficiencies that stem from scale‑driven supply contracts and localized menu innovation that competitors cannot replicate quickly.
Risk. The growth pillar is the model’s weakest (73), and revenue is only expanding at 6.7% YoY – a pace that could stall if Chinese consumer spending shifts or if local rivals erode KFC’s market share. A PE of 16.4×, while reasonable, already embeds expectations of continued double‑digit growth; a slowdown would compress the multiple and trigger a sell‑off. The bear case materialises if quarterly margins dip below 7% and the company’s debt‑to‑equity climbs above 0.5, pressuring the balance sheet and forcing a cut to buybacks.
Horizon. 1-3 yr $61.34 (analyst consensus (n=21)) — fundamentals + valuation re-rating. 5 yr $89.81 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $133.23 if current growth sustains into durable earnings power.
28. FISV — Fiserv, Inc. · score 75.9
Sector n/a · price $50.61 · 1Y $67.37 · 5Y $98.64 · 10Y $146.32
FCF $4.1b B · Rev +9.3% B · D/E n/a · P/E 8.6x A- · PEG 2.38 C
Why now. Our model gives FISV a Quality‑growth score of 75.9, anchored by a Quality pillar of 82 – the strongest of the three – meaning the business consistently generates cash and margins. The free cash flow of $4.1 B on a $27.0 B market cap yields a 15% FCF yield, while a 19.7% profit margin shows pricing power in its payments‑processing platform. Coupled with 9.3% year‑over‑year revenue growth, the company can keep compounding earnings, and the bull case rests on this cash‑rich, high‑margin engine continuing to scale.
Moat. Fiserv’s moat lies in its integrated payments‑processing suite that locks in large merchants and financial institutions through deep API integrations and data‑rich services, creating switching costs that competitors cannot quickly replicate. The steady 12.2% ROE reflects the pricing advantage earned from being the backbone of transaction flows for thousands of clients, reinforcing durable cash generation.
Risk. The Bull Rankings model’s reverse DCF implies a -16% annual free‑cash‑flow growth rate for the next decade – a stark contrast to the actual 9.3% revenue growth, indicating the market is already pricing in unrealistic optimism; a slowdown to the historical growth pace would force the stock toward its 52‑week low. The bear case materializes if FCF growth stalls, eroding the valuation cushion and triggering a sell‑off.
Horizon. 1-3 yr $67.37 (analyst consensus (n=27)) — fundamentals + valuation re-rating. 5 yr $98.64 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $146.32 if current growth sustains into durable earnings power.
29. ULTA — Ulta Beauty, Inc. · score 74.8
Specialty Retail · price $489.47 · 1Y $623.58 · 5Y $912.99 · 10Y $1,354
FCF $1.1b C+ · Rev +11.3% B · D/E 0.89 B · P/E 18.3x B+ · PEG 1.67 C+
Why now. Specialty Retail · market cap $21.0b. Down 32% from 52-week high of $714.97 — deep drawdown territory. Revenue growing +11%, comfortably above the S&P median. 24 sell-side analysts rate this a Buy with a mean 1-yr target of $623.58 (implying +27% upside).
Moat. ROE 46% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 95% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Down 32% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Horizon. 1-3 yr $623.58 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $912.99 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $1,354 if current growth sustains into durable earnings power.
30. EME — EMCOR Group, Inc. · score 74.7
Engineering & Construction · price $760.27 · 1Y $1,000 · 5Y $1,263 · 10Y $1,619
FCF $1.1b C+ · Rev +18.3% B+ · D/E 0.13 A- · P/E 25.5x B · PEG 0.40 A
Why now. Engineering & Construction · market cap $33.9b. Down 20% from 52-week high of $951.96 — deep drawdown territory. Revenue growing +18%, comfortably above the S&P median. PEG 0.40 — paying under fair value for the growth rate. 7 sell-side analysts rate this a Buy with a mean 1-yr target of $1,000 (implying +32% upside).
Moat. ROE 35% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which.
Risk. Value re-rating depends on a catalyst. Without one — analyst day, divestiture, margin recovery, capital return — the stock can stay cheap on these multiples for years.
Horizon. 1-3 yr $1,000 (analyst consensus (n=7)) — multiple re-rating thesis requires a catalyst. 5 yr $1,263 at ~11% CAGR — dividend + buyback compounding. 10 yr $1,619 if the moat survives secular pressure.
Methodology footnote
Every pick on this list comes out of the same quality-growth model — one 0–100 score blending quality, growth, and value — applied to every US-listed common stock with a market cap above $1B. Each pick's score breakdown is auditable from the home page — click the ticker on the rankings page to see exactly which grades produced the number. Not investment advice. See terms for full disclosures.